Vanda Pharmaceuticals announced that its newly FDA-approved motion sickness drug, NEREUS™ (tradipitant), will sponsor the No. 47 car in the NTT IndyCar Series. This partnership highlights the drug as the first new prescription treatment for motion-induced vomiting in 47 years, aligning with the high-speed, focused environment of IndyCar racing. NEREUS™ offers a modern option for millions affected by motion sickness, representing a significant advancement in treatment. The sponsorship will be visible at select 2026 IndyCar events, symbolizing both innovation and performance under challenging conditions.
Evercore ISI raised Ross Stores' price target to $276, suggesting a 12.5% upside from its current $245.36 price. The boost reflects strong expectations for Q2, with projected revenues of $6.10 billion (up 10.7%) and earnings per share of $1.92 (up 23...
Fabrinet is set to report strong Q3 2026 earnings with revenue forecasted at about $1.276 billion, a 41% increase year-over-year, driven by demand in Telecom and Data Center sectors. Earnings per share are expected to rise 45% to $3.81, reflecting ro...
Jernigan Capital, a REIT specializing in financing self-storage facilities, saw its stock rise over 11% to $24.00, reaching a new 52-week high. Analysts have a consensus "Moderate Buy" rating with an average 12-month price target of $27.50, suggestin...
CrowdStrike, a leading cybersecurity firm, has seen its stock price increase by 85% year-to-date, reaching a market cap over $220 billion. Investment firm Cowen & Co. reiterated a "Buy" rating and raised the price target to $235, citing strong financ...
Alpha Cognition Inc. reported a 71% quarter-over-quarter revenue increase to $6.0 million in Q2 2026, driven by strong demand for its ZUNVEYL product with 37% growth in bottles dispensed. Despite only 16% payer implementation, prescription and facili...
